Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
STU:UNJ's 5-Year Yield-on-Cost % is ranked better than 97.46% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs STU:UNJ: 35.25
United Laboratories International Holdings (STU:UNJ) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
United Laboratories International Holdings 5-Year Yield-on-Cost % Related Terms
STU:UNJ vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
United Laboratories International Holdings 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
United Laboratories International Holdings (STU:UNJ) has a 5-Year Yield-on-Cost % of 35.25 as of Aug. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on United Laboratories International Holdings and its competitors. This is 113% above median its historical median of 16.53. Over the past decade, United Laboratories International Holdings' 5-Year Yield-on-Cost % has ranged from 4.76 to 38.08. According to the industry distribution chart, United Laboratories International Holdings ranks #13 out of 511 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is United Laboratories International Holdings' 5-Year Yield-on-Cost % too high?
United Laboratories International Holdings' current 5-Year Yield-on-Cost % of 35.25 is 113% above median its 10-year median of 16.53. Over the past 10 years, this metric has ranged from a low of 4.76 to a high of 38.08. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.28. United Laboratories International Holdings' value of 35.25 is 1446.1% above this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #13 out of 511 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Laboratories International Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #13 out of 511 companies for 5-Year Yield-on-Cost %. This places United Laboratories International Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.28. United Laboratories International Holdings' value of 35.25 is 1446.1% above this benchmark. Historically, United Laboratories International Holdings' own 5-Year Yield-on-Cost % has ranged from 4.76 to 38.08 over the past decade. While the company's 10-year median is 16.53 vs. the industry median of 2.28, United Laboratories International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current 5-Year Yield-on-Cost % of 35.25 is 1446.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current 5-Year Yield-on-Cost % is 35.25, which is 113% above median its own 10-year median of 16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (STU:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.92, compared to a current price of €0.96 — trading 3.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 35.25, which is 113% above median its 10-year median of 16.53 and 1446.1% above the Drug Manufacturers industry median of 2.28. United Laboratories International Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For United Laboratories International Holdings (STU:UNJ), the current 5-Year Yield-on-Cost % is 35.25 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (STU:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €0.96 is trading 3.8% above its estimated GF Value™ of €0.92.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for STU:UNJ:
5-Year Yield-on-Cost %: 35.25 (113% above median its 10-year median of 16.53)
GF Value™: €0.92 vs. price of €0.96 (3.8% above fair value)
Industry Position: 1446.1% above the Drug Manufacturers median (#13 of 511)
No single metric tells the full story. See the STU:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
65GF Score
Get the complete analysis for STU:UNJ
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNJ has been successfully added to your 
